Table 4. SAE among patients treated for ovarian cancer.
| SAE | No. of patients | No. of cases* | ||
|---|---|---|---|---|
| No. | % | |||
| Blood and lymphatic system disorders | 5 | 27.8 | 22 | |
| Neutropenia | 4 | 22.2 | 15 | |
| Febrile neutropenia | 4 | 22.2 | 6 | |
| Thrombocytopenia | 1 | 5.6 | 1 | |
| Gastrointestinal disorders | 1 | 5.6 | 1 | |
| Abdominal pain upper | 1 | 5.6 | 1 | |
| General disorders and administration site condition | 2 | 11.1 | 2 | |
| Pain | 1 | 5.6 | 1 | |
| Pyrexia | 1 | 5.6 | 1 | |
| Metabolism and nutrition disorders | 1 | 5.6 | 1 | |
| Hyponatremia | 1 | 5.6 | 1 | |
| Immune system disorders | 1 | 5.6 | 1 | |
| Hypersensitivity | 1 | 5.6 | 1 | |
| Hepatobiliary disorders | 1 | 5.6 | 1 | |
| Cholecystitis acute | 1 | 5.6 | 1 | |
| Infections and infestations | 1 | 5.6 | 1 | |
| Cellulitis | 1 | 5.6 | 1 | |
| Injury, poisoning and procedural complications | 1 | 5.6 | 1 | |
| Wound dehiscence | 1 | 5.6 | 1 | |
| Total | 10 | 55.6 | 30 | |
SAE, serious adverse events.
*Some patients had multiple cases of the indicated condition.